InvestorsObserver
Sign Up Login

CDAK Codiak Biosciences Inc

$0.69 $0.00 (-0.65%)
Add to Watchlist Compare
Overall

CDAK Stock Analysis Overview

What this means: InvestorsObserver gives Codiak Biosciences Inc (CDAK) an overall rank of 35, which is below average. Codiak Biosciences Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 35 means that 65% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

CDAK Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

CDAK Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

CDAK Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

CDAK Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

CDAK Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

CDAK Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

CDAK Stock Analysis Overview

What this means: InvestorsObserver gives Codiak Biosciences Inc (CDAK) an overall rank of 35, which is below average. Codiak Biosciences Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 35 means that 65% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full CDAK report

CDAK Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

CDAK Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

CDAK Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

CDAK Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

CDAK Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

CDAK Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Codiak Biosciences Inc (CDAK) Analyst Forecast

CDAK Price, Volume, Earnings, and Dividend Date

  • Last Price $0.69
  • Previous Close $0.69
  • Change $0.00
  • Open $0.65
  • Volume 119,769
  • Avg. Volume (100-day) 315,823
  • Market Cap 24,674,732
  • Days Range 0.65 - 0.7
  • 52-week Range 0.59 - 15.08
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 02/01/23
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 1.115
  • PEG Ratio —

Codiak Biosciences Inc (CDAK) Company Description

Codiak BioSciences Inc is a development-stage biopharmaceutical company focused on the development of exosome-based therapeutics for the treatment of a wide spectrum of diseases with high unmet medical need. The company have utilized engEx Platform to generate a pipeline of engineered exosomes, aimed at treating a broad range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease, infectious disease and rare disease.

Codiak Biosciences Inc (CDAK) Stock Chart

View Interactive CDAK chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
Oncolytics Biotech Inc (ONCY) (ONCY) $1.85
Glycomimetics Inc (GLYC) (GLYC) $2.29
SC Pharmaceuticals Inc (SCPH) (SCPH) $7.05
Vectivbio Holding Ag (VECT) (VECT) $8.22
Oyster Point Pharma Inc (OYST) (OYST) $11.12
Actinium Pharmaceuticals Inc (ATNM) (ATNM) $11.27
Lava Therapeutics N.V. (LVTX) (LVTX) $7.31
Mersana Therapeutics Inc (MRSN) (MRSN) $7.25
Viking Thera (VKTX) (VKTX) $4.26
Biocardia Inc (BCDA) (BCDA) $1.79